Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Completion Rate and Side-Effect Profile of Three-Month Isoniazid and Rifapentine Treatment for Latent Tuberculosis Infection in an Urban County Jail. Open forum infectious diseases Juarez-Reyes, M., Gallivan, M., Chyorny, A., O'Keeffe, L., Shah, N. S. 2016; 3 (1): ofv220-?

Abstract

In an urban jail population, 3 months of isoniazid and rifapentine (3HP) was associated with an 85% latent tuberculosis infection treatment completion rate compared with 18% in a standard 9-month isoniazid treatment group. Among the 91 patients who started 3HP therapy, there were 2 treatment discontinuations from adverse drug reactions.

View details for DOI 10.1093/ofid/ofv220

View details for PubMedID 26885547

View details for PubMedCentralID PMC4753347